We are live on ! Find out more
CODX

Co-Diagnostics

7 hedge funds and large institutions have $327K invested in Co-Diagnostics in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

40% more funds holding

Funds holding: 57 (+2)

0.19% less ownership

Funds ownership: 1.93%1.74% (-0.19%)

48% less capital invested

Capital invested by funds: $625K → $327K (-$298K)

Holders
7
Holders Change
+2
Holders Change %
+40%
% of All Funds
0.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
3
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

CODX Hedge Fund Activity: Q4 2018 in Review

7 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2018, worth a combined $327K — down 48% from $625K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CODX positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was HighTower Advisors, adding an estimated $35.8K. The largest seller was Vanguard Group, cutting an estimated $98.5K.

  • 7 institutional investors held Co-Diagnostics (CODX) as of Q4 2018, up from 5 in Q3 2018.
  • Funds reported $327K of Co-Diagnostics stock for Q4 2018, down 48% quarter-over-quarter.
  • 2 funds opened new Co-Diagnostics positions in Q4 2018 and 0 closed out, a net change of +2 holders.
  • The largest Co-Diagnostics buyer in Q4 2018 was HighTower Advisors, an estimated $35.8K added.
  • The largest Co-Diagnostics seller in Q4 2018 was Vanguard Group, an estimated $98.5K sold.

Based on aggregated 13F filings for Q4 2018.